NCT00841035View on ClinicalTrials.gov

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

erlotinib

Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.

Trial Locations (1)

35294-0016

University of Alabama at Birmingham,Comprehensive Cancer Center, Birmingham

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

University of Alabama at Birmingham

OTHER